Compare CSTE & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | XGN |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 71.2M |
| IPO Year | 2012 | 2014 |
| Metric | CSTE | XGN |
|---|---|---|
| Price | $1.78 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 163.0K | ★ 409.1K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.43 | $8.12 |
| Revenue Next Year | $2.83 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $2.59 |
| 52 Week High | $2.58 | $12.23 |
| Indicator | CSTE | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 54.82 |
| Support Level | $1.42 | $2.68 |
| Resistance Level | $1.76 | $5.55 |
| Average True Range (ATR) | 0.12 | 0.41 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 19.74 | 22.10 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa), of which it derives maximum revenue from United States.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.